DCF Advisers’s Lineage Cell Therapeutics LCTX Stock Holding History

DCF Advisers’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-107,751	Closed	-$54.1K	–	93
2024 Q4	$54.1K	Hold	107,751	–	–	0.03%	84
2024 Q3	$97.5K	Hold	107,751	–	–	0.05%	93
2024 Q2	$107K	Hold	107,751	–	–	0.06%	88
2024 Q1	$159K	Buy	107,751 +13,000	+14%	+$14.7K	0.1%	75
2023 Q4	$103K	Buy	94,751 +12,000	+15%	+$13.1K	0.07%	74
2023 Q3	$97.6K	Buy	82,751 +67,751	+452%	+$92.2K	0.07%	90
2023 Q2	$21.1K	Buy	+15,000	New	+$20.7K	0.01%	89
2022 Q2	–	Sell	-53,000	Closed	-$82K	–	84
2022 Q1	$82K	Sell	53,000 -32,000	-38%	-$49.7K	0.05%	65
2021 Q4	$208K	Sell	85,000 -2,000	-2%	-$4.68K	0.1%	69
2021 Q3	$219K	Buy	87,000 +12,500	+17%	+$32.1K	0.12%	75
2021 Q2	$212K	Buy	74,500 +53,500	+255%	+$138K	0.11%	89
2021 Q1	$49K	Buy	+21,000	New	+$50.4K	0.02%	103

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return